Connect Biopharma Holdings Limi
CNTB
Positions held
Your positionsCNTB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $55.46M | Enterprise value | $24.57M | Trailing P/E | — | Forward P/E | -1.26 |
| PEG | — | Price / book | 2.06 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 56.7% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -6.4% |
| Profit margin | 0.0% | ROE | -140.5% | ROA | -69.7% | Debt / equity | 0.02 |
| Current ratio | 2.37 | Free cash flow | -$34.71M | Analyst recommendation | strong_buy | Mean target | $5.88 |
| 52w high | $3.82 | 52w low | $0.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $2.8M | $0.2M | $0.0M | $0.0M | $0.0M |
| Op margin | -636.0% | -11601.8% | — | -110481.3% | -27966.7% |
| Net income | -$17.3M | -$19.4M | -$15.1M | -$17.2M | -$12.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.6M | -$19.6M | -$15.5M | -$17.7M | -$13.4M |
- Revenue +1538% vs prior quarter ($2.8M vs $0.2M).
- Operating margin expanded to -636%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $26.0M | $0.0M | $0.0M | — |
| Op margin | -90740.6% | -86.2% | — | — | — |
| Net income | -$55.5M | -$15.6M | -$62.1M | -$118M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$58.1M | -$22.5M | -$69.1M | -$117M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-04 · Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
2026-09-30 · Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
2026-09-30 · BC-Most Active Stocks
2026-09-22 · Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
2026-09-22 · Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating
2026-09-15 · Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
2026-09-03 · Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-12 · Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Price (daily)
Full chart · RSI · MACD · patterns